Benson Investment Management Company Inc. Trims Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Benson Investment Management Company Inc. decreased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 36,512 shares of the specialty pharmaceutical company’s stock after selling 130 shares during the period. Benson Investment Management Company Inc.’s holdings in Jazz Pharmaceuticals were worth $4,496,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 121 shares during the period. Venturi Wealth Management LLC lifted its stake in Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 350 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Robert W. Baird increased their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. TD Cowen reduced their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $177.00.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,253 shares of company stock valued at $1,001,434. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Trading Up 1.4 %

JAZZ opened at $123.16 on Tuesday. The business’s 50-day simple moving average is $122.29 and its 200-day simple moving average is $114.27. The company has a market cap of $7.45 billion, a P/E ratio of 17.35, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.